This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leibowitz, R. L. Articles by Tucker, S. J. Search for Related Content PubMed PubMed Citation Articles by Leibowitz, R. L. Articles by Tucker, S. J.

Treatment of Localized Prostate Cancer With Intermittent Triple Androgen Blockade: Preliminary Results in 110 Consecutive Patients

Compassionate Oncology Medical Group, Los Angeles, California, USA

Correspondence: Robert L. Leibowitz, M.D., Compassionate Oncology Medical Group, 2080 Century Park East, #601, Los Angeles, California 90067, USA. Telephone: 310-229-3555; Fax: 310-229-3554; e-mail: help{at}drsteventucker.com

Objectives. To determine the effectiveness of triple androgen blockade as an alternative to watchful waiting, radical prostatectomy or radiation therapy in the management of patients with clinical stage T1 to T3 prostate cancer.

Methods. The records of 110 consecutive patients were retrospectively evaluated. Patients were treated with a three-drug androgen blockade regimen, consisting of a luteinizing hormone-releasing hormone agonist (leuprolide or goserelin) plus an antiandrogen (flutamide or bicalutamide) plus finasteride (a 5-alpha-reductase inhibitor), followed by finasteride maintenance therapy, as the sole intervention. All patients refused local therapy and had their prostates intact. Determinants of efficacy included serum prostate-specific antigen (PSA) levels and disease-specific survival.

Results. Patients were treated for a median of 13 months with triple androgen blockade. At baseline, mean PSA level was 13.2 ± 1.2 ng/ml (range, 0.39-100 ng/ml), and mean Gleason score was 6.6 ± 0.1 (range, 4-10). During treatment, PSA levels declined to 0.1 ng/ml in all patients, with a median time of 3 months. After a median follow-up of 36 months since initiation of treatment, PSA levels have remained stable in 105 of 110 patients (95.5%). At a median follow-up of 55 months (range, 38-125 months), the mean PSA level for the first 57 patients treated in this series is 1.88 ± 0.1 (range, 0-11.0 ng/ml). Only 9 of 110 (8.1%) patients have a PSA level 4.0 ng/ml. To date, no patient has received a second cycle of hormone blockade.

Conclusions. Although median follow-up is short, triple androgen blockade therapy followed by finasteride maintenance appears to be a promising alternative for the management of patients with clinically localized or locally advanced prostate cancer. Further study of this approach is warranted.

Key Words. Prostate cancer • Triple androgen blockade

This article has been cited by other articles:

				T. Nishiyama, Y. Hashimoto, and K. Takahashi The Influence of Androgen Deprivation Therapy on Dihydrotestosterone Levels in the Prostatic Tissue of Patients with Prostate Cancer Clin. Cancer Res., November 1, 2004; 10(21): 7121 - 7126. [Abstract] [Full Text] [PDF]

				M. R. Cooperberg, D. P. Lubeck, M. V. Meng, S. S. Mehta, and P. R. Carroll The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management J. Clin. Oncol., June 1, 2004; 22(11): 2141 - 2149. [Abstract] [Full Text] [PDF]

				B. A. Hellerstedt and K. J. Pienta The Current State of Hormonal Therapy for Prostate Cancer CA Cancer J Clin, May 1, 2002; 52(3): 154 - 179. [Abstract] [Full Text] [PDF]